The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid developments, and government initiatives. So, quality biotech stocks Incyte Corporation (INCY), Corcept Therapeutics Incorporated (CORT), and Entrada Therapeutics, Inc. (TRDA) could be worth buying.
The industry is consistently evolving with advanced technologies like AI. The global Generative AI in Biotech Market is estimated to be worth $472 million by 2032, increasing at a 24.9% CAGR.
